Contact UsDiana Bartlett
Assistant Vice President,
Phone: (909) 607-9864
Email: diana_bartlett[at symbol]kgi.edu
Team Masters Projects 2012-13
Review alternative feedstock's for the production of advanced biofuels as defined by the state and federal biofuels policies. Evaluate advanced biofuel process efficiencies and potential improvements in novel biochemical pathways
Recommend a course of action for Amicus Therapeutics' involvement in shaping newborn screening of Fabry disease and increasing the detection of patients with these diseases
Astellas Pharma US, Inc.
Conduct strategic planning for Astellas to become a Global Oncology Leader with an emphasis on oncology portfolio planning and management
Beijing Zhongmei Aochi Biotech Co.LtD.
Perform a technology and market assessment of innovative anti-aging appoaches available in the U.S. for potential implementation in China
BioMarin Pharmaceutical Inc.
Evaluate the clinical product cold chain landscape for BioMarin and develop a template strategy for a more robust, integrated cold chain solution. Provide specific recommendations and testing support for new solutions, enabling BioMarin to continue volume expansion of their clinical product portfolio
Castle Biosciences Incorporated
Produce a detailed analysis of a number of rare cancers and incorporate these results into a rare cancer database. Use the newly formed database to identify rare cancers with poor prognostic accuracy and strong clinical need for improved biomarkers or new diagnostic tests
City of Hope
Investigate personalized medicine to understand the market adoption of targeted/personalized versus conventional therapies. Generate a quantitative model that predicts the adoption rate of these personalized therapies based on key stakeholder behaviors including the impact on quality of life, treatment costs and the changing dynamics of the healthcare marketplace
Eli Lilly and Company
Review the traditional method pharmaceutical companies use to design and develop new medicines, focusing on the Draft Launch Label (DLL) and the Manufacturing Marketed Forms Agreement (MMFA) requirements. Test whether additional input from all the stakeholders throughout the product design and development stage using co-creation techniques could lead to a product with an improved value to patients
Provide an assessment of the competitive landscape to identify value drivers for the company's current endovascular aortic repair technology. Evaluate the technology with regard to physiological constraints using finite element analysis and customized protocols for empirical characterization. Provide recommendations to optimize therapeutic performance, reduce operating costs, increase the quality of life for repair candidates and enhance market strategy
Gilead Sciences Fall 2012
Provide a market assessment of the current landscape for mammalian cell line development (CLD) used for monoclonal antibody production. Based on the results of the investigation, make a recommendation to narrow the scope to technologies Gilead can bring in-house
Gilead Sciences (Spring 2013)
A major technological advancement that has played a significant role in advancing process understanding is the increase and evolution of high throughput, rapid, micro and nano-scale analytical technology. These technologies hold the promise of accelerating and defining the design space of biological processes. The aim of this project is to identify, evaluate and recommend high throughput analytical technologies that can be used for rapid bioprocess development. The recommendations must be capable of elucidating the bioprocess design space (QbD enabling), ease of integration into high-throughput upstream and downstream technologies and lead to resource efficiency.
Life Technologies Corporation (forensics)
Identify new market opportunities and challenges for an integrated human DNA identification technology that can decentralize and streamline forensic testing
Life Technologies Corporation (water testing)
Identify current and future needs and opportunities within the water testing marketplace
Meditope Biosciences, Inc. (Spring 2013)
Assessed the current landscape of monoclonal antibody and antibody-drug conjugate (ADC) development. Made recommendations on potential partnerships that would facilitate Meditope's clinical development of their own ADC with the goal of expediency while simultaneously showcasing Meditope's unique platform technology in the marketplace.
Develop devices and methodologies to improve existing agricultural technologies
Proteus Digital Health, Inc.
Based on expert interviews with coaches and trainers, develop improvements in data processing algorithms, mobile-device software, or hardware modifications to complement Proteus' adhesive patch, which provides continuous sensing of ECG, 3-axis accelerometry, and surface temperature. Demonstrate how wirelessly monitoring various metrics will enable the Proteus patch to allow coaches and trainers to make more informed decisions concerning a player's performance and safety during training and/or competition
Questcor Pharmaceuticals, Inc.
Research and evaluate new market opportunities for Acthar® Gel in various clinical settings. Conduct interviews with key opinion leaders, perform market analysis and incorporate case studies in support of potential Acthar® Gel clinical opportunities
Regeneron Pharmaceuticals, Inc.
Survey companies and interview experts with experience in the High Temperature, Short Time (HTST) process as well as other approaches used to create viral barriers in the production of biological pharmaceuticals. Complete a white paper describing these survey findings focused on industry standards, industry trends, and the impact of viral barriers on the cost of goods
Terumo BCT, Inc.
Analyze market drivers for whole blood transfusion
Explore self-service technologies to recommend a business strategy to move forward and gain a competitive edge in the Pharmacy Benefit Management market. Evaluate emerging trends in the mobile device market to assist US Script in expanding its scope
Identify diagnostic opportunities within disease areas selected by Veracyte. Based upon these findings, survey the competitive landscape and customer profiles in the spring semester
Yumei Kidney Disease Hospital
Investigate US kidney and stem-cell technologies by evaluating existing companies and their proprietary technologies. Recommend to Yumei Kidney Disease Hospital the most ideal candidates for acquisition. This is KGI's first international TMP (along with Aochi Biotech Co.Ltd described earlier)